Evidence mapPaperPMID 42097975Full record

ArticleThe Journal of physiology2026

Chronic attenuation of brain leptin signalling is associated with early metabolic dysfunction in lean rats.

Cristina Pintado, Lorena Mazuecos, Óscar Gómez-Torres, Beatriz Merino, Elena Casanueva-Álvarez, Blanca Rubio, Emma Burgos-Ramos, Sara Artigas-Jerónimo, Eduardo Moltó, Inés María Ramos and 7 more

Abstract read
In one paragraph

Article in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Cristina PintadoBiochemistry Section, Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha (UCLM), Toledo, Spain.ORCID https://orcid.org/0000-0002-9369-8318
Lorena MazuecosDOE Research Group, Institute of Biomedicine, IDISCAM, Spain.ORCID https://orcid.org/0000-0002-7897-1304
Óscar Gómez-TorresBiochemistry Section, Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha (UCLM), Toledo, Spain.ORCID https://orcid.org/0000-0001-5492-3343
Beatriz MerinoUnit of Excellence, Institute of Molecular Biology and Genetics (IBGM), University of Valladolid-CSIC, Valladolid, Spain.ORCID https://orcid.org/0000-0002-4761-3977
Elena Casanueva-ÁlvarezUnit of Excellence, Institute of Molecular Biology and Genetics (IBGM), University of Valladolid-CSIC, Valladolid, Spain.ORCID https://orcid.org/0000-0002-5517-1275
Blanca RubioDOE Research Group, Institute of Biomedicine, IDISCAM, Spain.
Emma Burgos-RamosBiochemistry Section, Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha (UCLM), Toledo, Spain.
Sara Artigas-JerónimoDOE Research Group, Institute of Biomedicine, IDISCAM, Spain.ORCID https://orcid.org/0000-0002-0068-5738
Eduardo MoltóBiochemistry Section, Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha (UCLM), Toledo, Spain.
Inés María RamosDepartment of Analytical Chemistry and Food Technology, Regional Institute for Applied Scientific Research (IRICA), Faculty of Chemical Sciences and Technologies, University of Castilla-La Mancha (UCLM), Ciudad Real, Spain.ORCID https://orcid.org/0000-0002-4351-076X
Justa María PovedaDepartment of Analytical Chemistry and Food Technology, Regional Institute for Applied Scientific Research (IRICA), Faculty of Chemical Sciences and Technologies, University of Castilla-La Mancha (UCLM), Ciudad Real, Spain.ORCID https://orcid.org/0000-0002-2843-2249
Germán PerdomoUnit of Excellence, Institute of Molecular Biology and Genetics (IBGM), University of Valladolid-CSIC, Valladolid, Spain.ORCID https://orcid.org/0000-0002-2301-0012
Irene Cózar-CastellanoUnit of Excellence, Institute of Molecular Biology and Genetics (IBGM), University of Valladolid-CSIC, Valladolid, Spain.
Carmen ArribasBiochemistry Section, Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha (UCLM), Toledo, Spain.ORCID https://orcid.org/0000-0003-2645-234X
Ernesto Bernal-MizrachiGeriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Miami, FL, USA.
Antonio AndrésDOE Research Group, Institute of Biomedicine, IDISCAM, Spain.ORCID https://orcid.org/0000-0002-9892-8338
Nilda GallardoDOE Research Group, Institute of Biomedicine, IDISCAM, Spain.ORCID https://orcid.org/0000-0003-3211-569X

Funding

European Regional Development FundMinisterio de Ciencia e Innovación PID2021-128243OB-I00Ministerio de Ciencia e Innovación RTI2018-098643-B-I00NIH HHS DK132103NIH HHS DK133183NIH HHS R01-DK073716Universidad de Castilla-La Mancha 2021 GRIN-30987Universidad de Castilla-La Mancha 2022-GRIN-34280VA BX002728
6 · The paper itself

Abstract

Brain leptin signalling plays a central role in the regulation of energy balance and glucose homeostasis, yet its contribution to early metabolic dysfunction preceding overt obesity remains uncertain. In the present study, we examined the metabolic consequences of sustained attenuation of central leptin receptor signalling in lean rats. Adult animals received chronic i.c.v. infusion of a rat-specific leptin receptor antagonist (SLA) or vehicle for 21 days. SLA administration increased food intake with modest gains in body weight and visceral adiposity at the same time as maintaining normoleptinemia, and induced hepatic and pancreatic lipid accumulation, hyperinsulinemia, impaired glucose tolerance and hyperglucagonemia. These alterations were accompanied by hepatic glucagon resistance, as indicated by attenuated gluconeogenic gene induction and reduced CREB phosphorylation following in vivo glucagon stimulation. SLA-infused rats also exhibited elevated circulating total and branched-chain amino acids, reduced hepatic branched-chain α-ketoacid dehydrogenase activity and increased fibroblast growth factor 21 levels, consistent with disrupted glucagon-amino acid signalling. Together, these findings indicate that impaired central leptin signalling induces co-ordinated endocrine and metabolic disturbances in the absence of obesity, supporting a role for altered central neuroendocrine regulation in the early development of metabolic dysfunction. KEY POINTS: Chronic attenuation of brain leptin signalling is associated with early metabolic dysfunction in lean rats. Central leptin disruption leads to hyperglucagonemia, hepatic glucagon resistance and altered amino acid metabolism. Elevated fibroblast growth factor 21 levels and impaired branched-chain amino acid catabolism reflect early liver-α-cell axis dysregulation. This model provides insight into neuroendocrine drivers of non-obese prediabetes.

Indexed as

BrainLeptinReceptors, LeptinSignal TransductionAnimalsFibroblast Growth FactorsGlucagonLiverMaleRatsRats, Sprague-Dawleyfibroblast growth factor 21Fibroblast Growth FactorsGlucagonLeptinReceptors, Leptinamino acid metabolismbrain leptin signallingglucagon resistanceliver–α‐cell axisneuroendocrine regulationprediabetes

Identifiers

PMID42097975
PMCPMC13267677

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.